Economic implications of the modern treatment paradigm of glioblastoma: an analysis of global cost estimates and their utility for cost assessment

References

• Mariotto AB, Robin Yabroff K, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–128.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Earle C, Fang C-H, et al. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010;102(2):82–88.
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot CA, Stupp R, Bent M. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Expert Rev Pharmacoecon Outcomes Res. 2009;9(3):235–241.
   PubMedGoogle Scholar
• Consumer price index estimated from the United States Bureau of Labor Statistics. 2017. Available from: http://www.bls.gov/data/inflation_calculator.htm
   Google Scholar
• OECD. Purchasing power parities (PPP) OECD.ORG: Organization for Economic Cooperation and Development. 2017. Available from: https://data.oecd.org/conversion/PURCHASING-POWER-PARITIES-PPP.HTM
   Google Scholar
• Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):iii–iv.
   Web of Science ®Google Scholar
• Kovic B, Xie F. Economic evaluation of bevacizumab for the first-line treatment of newly diagnosed glioblastoma multiforme. J Clin Oncol. 2015;33(20):2296–2302.
   PubMed Web of Science ®Google Scholar
• Ray S, Bonafede MM, Mohile NA. Treatment patterns, survival, and healthcare costs of patients with malignant gliomas in a large US commercially insured population. Am Health Drug Benefits. 2014;7(3):140–149.
   PubMedGoogle Scholar
• Messali A, Hay JW, Villacorta R. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol. 2013;15(11):1532–1542.
   PubMed Web of Science ®Google Scholar
• Wu B, Miao Y, Bai Y, et al. Subgroup economic analysis for glioblastoma in a health resource-limited setting. PLoS One. 2012;7(4):e34588.
   PubMed Web of Science ®Google Scholar
• Silverstein MD, Cascino TL, Harmsen WS. High-grade astrocytomas: resource use, clinical outcomes, and cost of care. Mayo Clin Proc. 1996;71(10):936–944.
   PubMed Web of Science ®Google Scholar
• Attenello FJ, Mukherjee D, Datoo G, et al. Use of gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol. 2008;15(10):2887–2893.
   PubMed Web of Science ®Google Scholar
• Xing WK, Shao C, Qi ZY, et al. The role of gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis. Drug Des Devel Ther. 2015;9:3341–3348.
   PubMed Web of Science ®Google Scholar
• Barr JG, Grundy PL. The effects of the NICE technology appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma. Br J Neurosurg. 2012;26(6):818–822.
   PubMed Web of Science ®Google Scholar
• John-Baptiste AA, Wu W, Rochon P, et al. A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer. PLoS One. 2013;8(5):e62614.
   PubMed Web of Science ®Google Scholar
• Mendez I, Jacobs P, MacDougall A, et al. Treatment costs for glioblastoma multiforme in Nova Scotia. Can J Neurol Sci. 2001;28(1):61–65.
   PubMed Web of Science ®Google Scholar
• Esteves S, Alves M, Castel-Branco M, et al. A pilot cost-effectiveness analysis of treatments in newly diagnosed high-grade gliomas: the example of 5-aminolevulinic acid compared with white-light surgery. Neurosurgery. 2015;76(5):552–562; discussion 562.
   PubMed Web of Science ®Google Scholar
• Rogers G, Garside R, Mealing S, et al. Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis. Pharmacoeconomics. 2008;26(1):33–44.
   PubMed Web of Science ®Google Scholar
• Johannesen TB, Norum J, Lote K, et al. A cost-minimising analysis of standard radiotherapy and two experimental therapies in glioblastoma. Radiother Oncol. 2002;62(2):227–231.
   PubMed Web of Science ®Google Scholar
• Henaine AM, Paubel N, Ducray F, et al. Current trends in the management of glioblastoma in a French University Hospital and associated direct costs. J Clin Pharm Ther. 2016;41(1):47–53.
   PubMed Web of Science ®Google Scholar
• Bernard-Arnoux F, Lamure M, Ducray F, et al. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2016;18(8):1129–1136.
   PubMed Web of Science ®Google Scholar
• Lamers LM, Stupp R, van den Bent MJ, EORTC 26981/22981 NCI-C CE3 Intergroup Study, et al. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 intergroup study. Cancer. 2008;112(6):1337–1344.
   PubMed Web of Science ®Google Scholar
• Latif AZ, Signorini D, Gregor A, et al. The costs of managing patients with malignant glioma at a neuro-oncology clinic. Br J Neurosurg. 1998;12(2):118–122.
   PubMed Web of Science ®Google Scholar
• Wasserfallen JB, Ostermann S, Pica A, et al. Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death. Cancer. 2004;101(9):2098–2105.
   PubMed Web of Science ®Google Scholar
• Burton E, Ugiliweneza B, Woo S, et al. A surveillance, epidemiology and end results-Medicare data analysis of elderly patients with glioblastoma multiforme: treatment patterns, outcomes and cost. Mol Clin Oncol. 2015;3(5):971–978.
   PubMed Web of Science ®Google Scholar
• Mabasa VH, Taylor SC. Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia. J Oncol Pharm Pract. 2006;12(2):105–111.
   PubMedGoogle Scholar
• Ruiz-Sanchez D, Peinado II, Alaguero-Calero M, et al. Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences. Oncol Lett. 2016;12(3):1935–1940.
   PubMed Web of Science ®Google Scholar
• Wasserfallen JB, Ostermann S, Leyvraz S, et al. Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death. Neuro Oncol. 2005;7(2):189–195.
   PubMed Web of Science ®Google Scholar
• Martikainen JA, Kivioja A, Hallinen T, et al. Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. Pharmacoeconomics. 2005;23(8):803–815.
   PubMed Web of Science ®Google Scholar
• Slof J, Díez Valle R, Galván J. Cost-effectiveness of 5-aminolevulinic acid-induced fluorescence in malignant glioma surgery. Neurologia. 2015;30(3):163–168.
   PubMed Web of Science ®Google Scholar